1. Home
  2. CPIX vs SAVA Comparison

CPIX vs SAVA Comparison

Compare CPIX & SAVA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • CPIX
  • SAVA
  • Stock Information
  • Founded
  • CPIX 1999
  • SAVA 1998
  • Country
  • CPIX United States
  • SAVA United States
  • Employees
  • CPIX N/A
  • SAVA N/A
  • Industry
  • CPIX Biotechnology: Pharmaceutical Preparations
  • SAVA Biotechnology: Pharmaceutical Preparations
  • Sector
  • CPIX Health Care
  • SAVA Health Care
  • Exchange
  • CPIX Nasdaq
  • SAVA Nasdaq
  • Market Cap
  • CPIX 68.7M
  • SAVA 70.5M
  • IPO Year
  • CPIX 2009
  • SAVA N/A
  • Fundamental
  • Price
  • CPIX $5.15
  • SAVA $2.10
  • Analyst Decision
  • CPIX
  • SAVA Buy
  • Analyst Count
  • CPIX 0
  • SAVA 3
  • Target Price
  • CPIX N/A
  • SAVA $54.50
  • AVG Volume (30 Days)
  • CPIX 38.4K
  • SAVA 1.3M
  • Earning Date
  • CPIX 05-06-2025
  • SAVA 05-08-2025
  • Dividend Yield
  • CPIX N/A
  • SAVA N/A
  • EPS Growth
  • CPIX N/A
  • SAVA N/A
  • EPS
  • CPIX N/A
  • SAVA N/A
  • Revenue
  • CPIX $41,083,299.00
  • SAVA N/A
  • Revenue This Year
  • CPIX N/A
  • SAVA N/A
  • Revenue Next Year
  • CPIX N/A
  • SAVA N/A
  • P/E Ratio
  • CPIX N/A
  • SAVA N/A
  • Revenue Growth
  • CPIX 5.82
  • SAVA N/A
  • 52 Week Low
  • CPIX $1.04
  • SAVA $1.15
  • 52 Week High
  • CPIX $7.25
  • SAVA $42.20
  • Technical
  • Relative Strength Index (RSI)
  • CPIX 53.74
  • SAVA 58.24
  • Support Level
  • CPIX $4.81
  • SAVA $1.96
  • Resistance Level
  • CPIX $6.21
  • SAVA $2.22
  • Average True Range (ATR)
  • CPIX 0.50
  • SAVA 0.15
  • MACD
  • CPIX -0.00
  • SAVA 0.00
  • Stochastic Oscillator
  • CPIX 38.00
  • SAVA 51.09

About CPIX Cumberland Pharmaceuticals Inc.

Cumberland Pharmaceuticals Inc is a specialty pharmaceutical company focused on the acquisition, development, and commercialization of branded prescription pharmaceutical products. The Company has one operating segment which is specialty pharmaceutical products. The company's primary target markets are hospital acute care, gastroenterology, rheumatology, and oncology. The company promotes its approved products through its hospital, field, and oncology sales divisions in the United States and establishes a network of international partners to register and provide medicines to patients in their countries. The company's revenue is derived from the product sales of FDA-approved pharmaceutical brands. Its brands include Acetadote, Caldolor, Kristalose, Omeclamox, Sancuso, Vaprisol and Vibativ.

About SAVA Cassava Sciences Inc.

Cassava Sciences Inc is a clinical-stage biotechnology company engaged in developing a scientific approach for the treatment and detection of Alzheimer's disease. Its therapeutic product candidate is called simufilam, and it is a novel treatment for Alzheimer's disease; and investigational diagnostic product candidate is called SavaDx and it is a novel way to detect the presence of Alzheimer's disease from a small sample of blood, possibly years before the overt appearance of clinical symptoms. It is currently conducting two randomized placebo-controlled Phase 3 clinical trials of oral simufilam in patients with Alzheimer's disease dementia. It has one business segment: the development of novel drugs and diagnostics.

Share on Social Networks: